Key Points
- Director Barbara-Jean Bormann-Kennedy sold 15,000 shares on Dec. 12 at an average price of $7.09 for $106,350, trimming her holding by 9.52% to 142,500 shares valued at about $1.01M.
- Shares opened at $7.05 and were trading down ~1.7%; the stock has a 52‑week range of $3.14–$10.08, a market cap of roughly $1.17B and a negative P/E of -70.49.
- Analysts show mixed views but a consensus of "Moderate Buy" with an average price target of $9.50, ranging from sell to outperform across firms.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) Director Barbara-Jean Bormann-Kennedy sold 15,000 shares of the firm's stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $7.09, for a total value of $106,350.00. Following the transaction, the director directly owned 142,500 shares of the company's stock, valued at $1,010,325. This represents a 9.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Xeris Biopharma Trading Down 1.7%
Shares of Xeris Biopharma stock opened at $7.05 on Tuesday. Xeris Biopharma Holdings, Inc. has a 52 week low of $3.14 and a 52 week high of $10.08. The company's 50-day moving average price is $7.96 and its two-hundred day moving average price is $6.83. The stock has a market cap of $1.17 billion, a PE ratio of -70.49 and a beta of 0.58.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. On average, equities analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.
Hedge Funds Weigh In On Xeris Biopharma
Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Xeris Biopharma by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company's stock worth $44,522,000 after purchasing an additional 210,581 shares during the period. Geode Capital Management LLC lifted its position in Xeris Biopharma by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company's stock worth $17,052,000 after buying an additional 244,862 shares in the last quarter. Qube Research & Technologies Ltd boosted its stake in shares of Xeris Biopharma by 6.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company's stock valued at $26,657,000 after buying an additional 185,063 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock valued at $15,317,000 after acquiring an additional 1,199,435 shares in the last quarter. Finally, Millennium Management LLC increased its stake in shares of Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company's stock worth $12,726,000 after acquiring an additional 369,420 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Xeris Biopharma in a research note on Wednesday, October 8th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Oppenheimer reissued an "outperform" rating and issued a $18.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Barclays began coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They set an "overweight" rating and a $9.00 price objective for the company. Finally, Leerink Partners lifted their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 19th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.50.
View Our Latest Stock Report on Xeris Biopharma
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
